// App-Quantinova.ai

: Pluripotent Cell-Derived Off-the-Shelf TCR-Less CAR-Targeted Cytotoxic T Cell Therapeutic for the Allogeneic Treatment of B Cell Malignancies

Researchers

Presenter

  • Raedun Clarke

Principal Investigators

  • Chia-Wei Chang

  • Mushtaq Husain

  • Yi-Shin Lai

  • Eigen Peralta

  • Laurel Stokely

  • Ramzey Abujarour

  • Jason Dinella

  • Tom Lee

  • Mochtar Pribadi

  • Helen Chu

  • Chris Truong

  • Mohsen Sabouri-Ghomi

  • Miguel Meza

  • Judith Feucht

  • Justin Eyquem

  • Jorge Mansilla-Soto

  • Isabelle Riviere

  • Michel Sadelain

  • Bahram Valamehr

Medical Centers

  • Mirati Therapeutics Inc., San Diego, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Graft-versus-host disease

  • Solid malignancies

Biomarkers

  • NANOG

  • Peripheral blood mononuclear cell

  • Cluster of Differentiation 107 Antigen-Like Family Member A

  • Cluster of Differentiation 25

  • Cluster of differentiation 69

  • Fc gamma RIIIa

  • Granzyme B

  • Interleukin-2

Drug/Treatment

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved